Stephen Liu: Overview of outcomes with 1L osimertinib
Stephen Liu shared a post on X about a recent paper by Kageaki Watanabe et al. published in JTO Clinical and Research Reports.
Authors: Kageaki Watanabe, Yukio Hosomi, Katsuhiko Naoki, Kohei Uemura, Hideo Kunitoh et al.
“Overview of outcomes with 1L osimertinib. At progression, continuation of osimertinib associated with shorter survival compared to those who discontinued (!), even after multivariate analysis and even among those who began chemotherapy.
Reminiscent of results from IMPRESS with gefitinib. Possible confounder here is delay to second line therapy in the continuation group. But PFS with osi + 2L chemo was 5.5m and 2L chemo alone was 7.4m. Prospective COMPEL trial will be very important.”
Source: Stephen Liu/X
Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.
As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.
More posts by Stephen Liu on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023